6Y8K

Crystal structure of CD137 in complex with the cyclic peptide BCY10916

This is a non-PDB format compatible entry.

Summary for 6Y8K

• Entry DOI: 10.2210/pdb6y8k/pdb
• Descriptor: Tumor necrosis factor receptor superfamily member 9, BCY10916, ACETATE ION, ... (8 entities in total)
• Functional Keywords: tnfrsf9, cd137, 4-1bb, bicyclic peptide, bicycle, bcy10916, signaling protein
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 2
• Total formula weight: 20206.67

Authors

Upadhyaya, P.,Kublin, J.,Dods, R.,Kristensson, J.,Lahdenranta, J.,Kleyman, M.,Repash, E.,Ma, J.,Mudd, G.,Van Rietschoten, K.,Haines, E.,Harrison, H.,Beswick, P.,Chen, L.,McDonnell, K.,Battula, S.,Hurov, K.,Keen, N. (deposition date: 2020-03-05, release date: 2021-02-03, Last modification date: 2024-11-06)

Primary citation

Upadhyaya, P.,Lahdenranta, J.,Hurov, K.,Battula, S.,Dods, R.,Haines, E.,Kleyman, M.,Kristensson, J.,Kublin, J.,Lani, R.,Ma, J.,Mudd, G.,Repash, E.,Van Rietschoten, K.,Stephen, T.,You, F.,Harrison, H.,Chen, L.,McDonnell, K.,Brandish, P.,Keen, N.
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
J Immunother Cancer, 9:-, 2021

PubMed Abstract: In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, termed tumor-targeted immune cell agonists (TICAs), based on constrained bicyclic peptides ().

PubMed: 33500260
DOI: 10.1136/jitc-2020-001762

Experimental method

X-RAY DIFFRACTION (2.011 Å)